Analytical Quality by Design Approach for a Stability-Indicating Method to Determine Apixaban and Its Related Impurities

被引:11
作者
Ellwanger, Jessica B. [1 ]
Wingert, Nathalie Ribeiro [1 ]
Volpato, Nadia Maria [1 ]
Garcia, Cassia Virginia [1 ]
Schapoval, Elfrides E. S. [1 ]
Steppe, Martin [1 ]
机构
[1] Univ Fed Rio Grande do Sul, Lab Pharmaceut Qual Control, Porto Alegre, RS, Brazil
关键词
Apixaban; Quality-by-design; AQbD; Experimental design; Drug impurities; ORALLY BIOAVAILABLE INHIBITOR; FACTOR XA INHIBITOR; HIGHLY POTENT; HPLC METHOD; DRUG; DEGRADATION; IDENTIFICATION; VALIDATION; TICAGRELOR; SAFETY;
D O I
10.1007/s10337-019-03815-9
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Quality by Design (QbD) is a systematic approach that takes predefined objectives and emphasizes process understanding and control. Analytical QbD (AQbD) is widely used when it comes to the development and optimization of analytical methods. Since impurities and contaminants may be present in the pharmaceutical product, current regulatory guidelines recommend monitoring these substances. Thus, the aim of this work was to develop and validate a fast and sensitive stability indicating method by high-performance liquid chromatography (HPLC) for the simultaneous determination of apixaban and three synthesis impurities using AQbD approach. Experiments were designed and assessed on MODDE 11 (Umetrics, Sweden) software and carried out in a Shimadzu LC-20A Prominence HPLC-DAD at 220 nm. Design of experiments was applied to achieve the optimum conditions through response surface methodology with four quantitative critical method parameters (CMPs): column temperature, flow rate, mobile phase pH and organic percentage. Besides, the chromatographic column was the fifth CMP taken as a qualitative variable. The HPLC method was established using an Inertsil CN-3 column at the temperature of 30 degrees C. The mobile phase consisted of methanol and water (50.2:49.8) at a flow rate of 1.015 mL/min with no pH adjustment. In order to confirm method selectivity excipients mixture was evaluated, as well as hydrolytic, photolytic, thermolytic, and oxidative conditions. The method was also validated for sensitivity (LOQ 0.5 mu g/mL, LOD 0.01-0.05 mu g/mL for impurities), linearity (concentration range 1-35 mu g/mL for APX and 0.5-10 mu g/mL for impurities, r > 0.999), precision (RSD <= 10%) and accuracy between levels (RSD < 3.0 for APX and < 4.0% for impurities). The application of AQbD led to a well-understood and validated analytical method that provided assured separation of APX and all significant impurities, turning it into a powerful decision-making tool for the analytical methodologies development.
引用
收藏
页码:65 / 75
页数:11
相关论文
共 39 条
[21]   Potential impurities of anxiolytic drug, clobazam: Identification, synthesis and characterization using HPLC, LC-ESI/MSn and NMR [J].
Kumar, Neeraj ;
Devineni, Subba Rao ;
Dubey, Shailendra Kumar ;
Kumar, Pramod .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2017, 137 :268-278
[22]   The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement [J].
Lassen, M. R. ;
Davidson, B. L. ;
Gallus, A. ;
Pineo, G. ;
Ansell, J. ;
Deitchman, D. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 (12) :2368-2375
[23]  
Mathad V.T., 2013, AM J ANAL CHEM, V4, P323, DOI [10.4236/ajac.2013.46041, DOI 10.4236/AJAC.2013.46041, 10.4236/ajac.2015.66052, DOI 10.4236/AJAC.2015.66052]
[24]   The syntheses and in vitro biotransformation studies of [14C]apixaban, a highly potent, selective, efficacious and orally bioavailable inhibitor of blood coagulation Factor Xa [J].
Maxwell, Brad D. ;
Tran, Scott B. ;
Chen, Shiang-Yuan ;
Zhang, Donglu ;
Chen, Bang-Chi ;
Zhang, Huiping ;
Bonacorsi, Samuel J., Jr. .
JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2011, 54 (08) :418-425
[25]  
Miller J. N., 2010, STAT CHEMOMETRICS AN, V6th
[26]   A morpholine-free process amenable convergent synthesis of apixaban: a potent factor Xa inhibitor [J].
Nevuluri, Narasimha Rao ;
Rapolu, Rajesh Kumar ;
Iqbal, Javed ;
Kandagatla, Bhaskar ;
Sen, Saikat ;
Dahanukar, Vilas H. ;
Oruganti, Srinivas .
MONATSHEFTE FUR CHEMIE, 2017, 148 (08) :1477-1482
[27]   Application of quality by design to the development of analytical separation methods [J].
Orlandini, Serena ;
Pinzauti, Sergio ;
Furlanetto, Sandra .
ANALYTICAL AND BIOANALYTICAL CHEMISTRY, 2013, 405 (2-3) :443-450
[28]   1-[3-aminobenzisoxazol-5′-yl]-3-trifluoromethyl-6-12′-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-13,4-c]-pyridin-7-one (BMS-740808) a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa 10.1016/j.bmel.2006.02.069 [J].
Pinto, Donald J. P. ;
Orwat, Michael J. ;
Quan, Mimi L. ;
Han, Qi ;
Galemmo, Robert A., Jr. ;
Amparo, Eugene ;
Wells, Brian ;
Ellis, Christopher ;
He, Ming Y. ;
Alexander, Richard S. ;
Rossi, Karen A. ;
Smallwood, Angela ;
Wong, Pancras C. ;
Luettgen, Joseph M. ;
Rendina, Alan R. ;
Knabb, Robert M. ;
Mersinger, Lawrence ;
Kettner, Charles ;
Bal, Steven ;
He, Kan ;
Wexler, Ruth R. ;
Lam, Patrick Y. S. .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (15) :4141-4147
[29]   Validation for chromatographic and electrophoretic methods [J].
Ribani, M ;
Bottoli, CBG ;
Collins, CH ;
Jardim, ICSF ;
Melo, LFC .
QUIMICA NOVA, 2004, 27 (05) :771-780
[30]  
Roy Jiben, 2002, AAPS PharmSciTech, V3, pE6